Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744523 · ClinicalTrials.gov registry record · NA
Proximal Protection With The Mo.Ma Device During Carotid Stenting
A NA study, sponsored by Medtronic Endovascular.
- Completed
- Registry status
- NA
- Development phase
- 262
- Enrollment target
NCT00744523: Completed NA study, sponsored by Medtronic Endovascular.
NCT00744523 is a NA study that has completed, run by Medtronic Endovascular. The registered enrollment target is 262 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00744523, a NA study, has completed, sponsored by Medtronic Endovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 262 participants
- Enrollment target
Study Summary
The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting
Primary Outcome
Number of subjects with one or more Major Adverse Cardiac and Cerebrovascular Events through 30 days after the procedure. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.
Interventions
- DEVICE Mo.Ma cerebral protection device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-03 |
| Phase | NA |
What the finished NCT00744523 record still lists
NCT00744523 is an interventional study that assigns participants to a tested intervention. The registered 262 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Mo.Ma cerebral protection device is the first listed.
NCT00744523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00744523 about?
NCT00744523 is a clinical study titled "Proximal Protection With The Mo.Ma Device During Carotid Stenting". The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting
What is the current status of trial NCT00744523?
This trial is currently completed. It is a NA study. The enrollment target is 262 participants. The study started on 2007-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00744523?
The interventions under investigation include: Mo.Ma cerebral protection device (DEVICE).
Who is sponsoring clinical trial NCT00744523?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00744523's enrollment target sits among peer trials
262 397th of 2000 higher than 1,604 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
- NCT06293703 · 262 participants · NA
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
- NCT06780137 · 262 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia